The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency

Haiqing Dai, Susan L. Johnson, Steven G. Terra, Thomas C. Marbury, William Smith, Harry Alcorn, Rebecca A. Boyd, Rong Wang, Tu T. Nguyen

Research output: Contribution to journalArticle

Abstract

AIMS: PF-734200 is a potent, selective inhibitor of DPP-IV. This two-part study evaluated the pharmacokinetics (PK) of oral 20mg PF-734200 in subjects with varying degrees of renal insufficiency or with end-stage renal disease (ESRD) requiring chronic haemodialysis (HD). The study also assessed the HD clearance of PF-734200 in ESRD. METHODS Part 1 included subjects with normal renal function or renal insufficiency but not on HD. Subjects received a single dose of 20mg PF-734200 while fasting and serum and urine samples were collected. In part 2, period 1, 1h after HD, a single 20-mg dose was given to subjects with ESRD and serum samples were collected. After a 7-day washout, subjects received another dose followed by collection of serum samples (period 2), during which HD was initiated 4h after dosing. Dialysate samples were collected to quantify amount of drug removed, from which HD clearance was calculated. The fraction of drug dialysed was calculated using an AUC-based method. RESULTS Systemic exposures of PF-734200 increased approximately 1.5-, 2.2-, 2.1- and 2.8-fold in subjects with mild, moderate, or severe renal insufficiency or ESRD, respectively, compared with subjects with normal renal function. The terminal half-life increased from 16.2h in subjects with normal renal function to 36.6h in subjects with ESRD. Approximately, 29% of PF-734200 in the body after a single-dose administration was dialysed by 4h HD. CONCLUSIONS Systemic exposure of PF-734200 increases with decreasing renal function. The effect of HD on drug removal is modest.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalBritish Journal of Clinical Pharmacology
Volume72
Issue number1
DOIs
StatePublished - Jul 1 2011

Fingerprint

Renal Insufficiency
Renal Dialysis
Pharmacokinetics
Chronic Kidney Failure
Kidney
Serum
Pharmaceutical Preparations
gosogliptin
Dialysis Solutions
Area Under Curve
Half-Life
Fasting
Urine

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency. / Dai, Haiqing; Johnson, Susan L.; Terra, Steven G.; Marbury, Thomas C.; Smith, William; Alcorn, Harry; Boyd, Rebecca A.; Wang, Rong; Nguyen, Tu T.

In: British Journal of Clinical Pharmacology, Vol. 72, No. 1, 01.07.2011, p. 85-91.

Research output: Contribution to journalArticle

Dai, H, Johnson, SL, Terra, SG, Marbury, TC, Smith, W, Alcorn, H, Boyd, RA, Wang, R & Nguyen, TT 2011, 'The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency', British Journal of Clinical Pharmacology, vol. 72, no. 1, pp. 85-91. https://doi.org/10.1111/j.1365-2125.2011.03954.x
Dai, Haiqing ; Johnson, Susan L. ; Terra, Steven G. ; Marbury, Thomas C. ; Smith, William ; Alcorn, Harry ; Boyd, Rebecca A. ; Wang, Rong ; Nguyen, Tu T. / The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency. In: British Journal of Clinical Pharmacology. 2011 ; Vol. 72, No. 1. pp. 85-91.
@article{6224b931d9a8427ab30356e1cae2b207,
title = "The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency",
abstract = "AIMS: PF-734200 is a potent, selective inhibitor of DPP-IV. This two-part study evaluated the pharmacokinetics (PK) of oral 20mg PF-734200 in subjects with varying degrees of renal insufficiency or with end-stage renal disease (ESRD) requiring chronic haemodialysis (HD). The study also assessed the HD clearance of PF-734200 in ESRD. METHODS Part 1 included subjects with normal renal function or renal insufficiency but not on HD. Subjects received a single dose of 20mg PF-734200 while fasting and serum and urine samples were collected. In part 2, period 1, 1h after HD, a single 20-mg dose was given to subjects with ESRD and serum samples were collected. After a 7-day washout, subjects received another dose followed by collection of serum samples (period 2), during which HD was initiated 4h after dosing. Dialysate samples were collected to quantify amount of drug removed, from which HD clearance was calculated. The fraction of drug dialysed was calculated using an AUC-based method. RESULTS Systemic exposures of PF-734200 increased approximately 1.5-, 2.2-, 2.1- and 2.8-fold in subjects with mild, moderate, or severe renal insufficiency or ESRD, respectively, compared with subjects with normal renal function. The terminal half-life increased from 16.2h in subjects with normal renal function to 36.6h in subjects with ESRD. Approximately, 29{\%} of PF-734200 in the body after a single-dose administration was dialysed by 4h HD. CONCLUSIONS Systemic exposure of PF-734200 increases with decreasing renal function. The effect of HD on drug removal is modest.",
author = "Haiqing Dai and Johnson, {Susan L.} and Terra, {Steven G.} and Marbury, {Thomas C.} and William Smith and Harry Alcorn and Boyd, {Rebecca A.} and Rong Wang and Nguyen, {Tu T.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1111/j.1365-2125.2011.03954.x",
language = "English (US)",
volume = "72",
pages = "85--91",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency

AU - Dai, Haiqing

AU - Johnson, Susan L.

AU - Terra, Steven G.

AU - Marbury, Thomas C.

AU - Smith, William

AU - Alcorn, Harry

AU - Boyd, Rebecca A.

AU - Wang, Rong

AU - Nguyen, Tu T.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - AIMS: PF-734200 is a potent, selective inhibitor of DPP-IV. This two-part study evaluated the pharmacokinetics (PK) of oral 20mg PF-734200 in subjects with varying degrees of renal insufficiency or with end-stage renal disease (ESRD) requiring chronic haemodialysis (HD). The study also assessed the HD clearance of PF-734200 in ESRD. METHODS Part 1 included subjects with normal renal function or renal insufficiency but not on HD. Subjects received a single dose of 20mg PF-734200 while fasting and serum and urine samples were collected. In part 2, period 1, 1h after HD, a single 20-mg dose was given to subjects with ESRD and serum samples were collected. After a 7-day washout, subjects received another dose followed by collection of serum samples (period 2), during which HD was initiated 4h after dosing. Dialysate samples were collected to quantify amount of drug removed, from which HD clearance was calculated. The fraction of drug dialysed was calculated using an AUC-based method. RESULTS Systemic exposures of PF-734200 increased approximately 1.5-, 2.2-, 2.1- and 2.8-fold in subjects with mild, moderate, or severe renal insufficiency or ESRD, respectively, compared with subjects with normal renal function. The terminal half-life increased from 16.2h in subjects with normal renal function to 36.6h in subjects with ESRD. Approximately, 29% of PF-734200 in the body after a single-dose administration was dialysed by 4h HD. CONCLUSIONS Systemic exposure of PF-734200 increases with decreasing renal function. The effect of HD on drug removal is modest.

AB - AIMS: PF-734200 is a potent, selective inhibitor of DPP-IV. This two-part study evaluated the pharmacokinetics (PK) of oral 20mg PF-734200 in subjects with varying degrees of renal insufficiency or with end-stage renal disease (ESRD) requiring chronic haemodialysis (HD). The study also assessed the HD clearance of PF-734200 in ESRD. METHODS Part 1 included subjects with normal renal function or renal insufficiency but not on HD. Subjects received a single dose of 20mg PF-734200 while fasting and serum and urine samples were collected. In part 2, period 1, 1h after HD, a single 20-mg dose was given to subjects with ESRD and serum samples were collected. After a 7-day washout, subjects received another dose followed by collection of serum samples (period 2), during which HD was initiated 4h after dosing. Dialysate samples were collected to quantify amount of drug removed, from which HD clearance was calculated. The fraction of drug dialysed was calculated using an AUC-based method. RESULTS Systemic exposures of PF-734200 increased approximately 1.5-, 2.2-, 2.1- and 2.8-fold in subjects with mild, moderate, or severe renal insufficiency or ESRD, respectively, compared with subjects with normal renal function. The terminal half-life increased from 16.2h in subjects with normal renal function to 36.6h in subjects with ESRD. Approximately, 29% of PF-734200 in the body after a single-dose administration was dialysed by 4h HD. CONCLUSIONS Systemic exposure of PF-734200 increases with decreasing renal function. The effect of HD on drug removal is modest.

UR - http://www.scopus.com/inward/record.url?scp=79958752041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958752041&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2011.03954.x

DO - 10.1111/j.1365-2125.2011.03954.x

M3 - Article

VL - 72

SP - 85

EP - 91

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 1

ER -